Literature DB >> 2727627

A new diagnostic approach to the patient with severe pneumonia.

J Sörensen1, P Forsberg, E Håkanson, R Maller, C Sederholm, L Sörén, C Carlsson.   

Abstract

36 patients with severe community-acquired pneumonia, treated in an intensive care unit (ICU), were examined in a prospective study using a comprehensive diagnostic program to establish an early etiological diagnosis. The resulting prompt and adequate antimicrobial therapy may have decreased the number of fatal cases. Special emphasis was placed on the use of a method incorporating fiberoptic bronchoscopy, together with protected brush sampling and bronchial lavage. An etiological diagnosis was established in 81% (29/36) of the cases. This etiological diagnosis was established within 48-72 h in 53% (19/36) of the patients, S. pneumoniae being the most frequent agent found (12 patients). This information, however, was poorly utilized since in only 11/19 of these patients was the antimicrobial therapy changed from a broad-spectrum antibiotic to a more specific narrow spectrum agent. The overall mortality rate was 22% (8/36). 7/8 patients who died had compromising factors. Most deaths in community-acquired pneumonia are still associated with pneumococcal infection. We conclude that fiberoptic bronchoscopy with brush samples via a plugged double lumen catheter provides the least misleading information concerning the etiological agent in pneumonia; sampling should be done as soon as possible after admission to the hospital, ideally before the need for ICU treatment; factors other than prompt antimicrobial therapy may influence the outcome of severe community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2727627     DOI: 10.3109/00365548909035678

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  15 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 2.  The pulmonary physician in critical care 1: pulmonary investigations for acute respiratory failure.

Authors:  J Dakin; M Griffiths
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

Review 3.  The pulmonary physician in critical care . 3: critical care management of community acquired pneumonia.

Authors:  S V Baudouin
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

4.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

5.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

6.  Impact of management guidelines on the outcome of severe community acquired pneumonia.

Authors:  N A Hirani; J T Macfarlane
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

7.  Grand Rounds--City Hospital, Nottingham. A complicated case of community acquired pneumonia.

Authors:  S R Johnson; I D Pavord
Journal:  BMJ       Date:  1996-04-06

Review 8.  Bronchoscopic diagnosis of pneumonia.

Authors:  V S Baselski; R G Wunderink
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

9.  Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.

Authors:  J Sörensen; B Kald; C Tagesson; M Lindahl
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

10.  Demonstration of circulating pneumococcal immunoglobulin G immune complexes in patients with community-acquired pneumonia by means of an enzyme-linked immunosorbent assay.

Authors:  Y Holloway; J A Snijder; W G Boersma
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.